Protagonist Therapeutics Inc
NASDAQ:PTGX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.83
48.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Protagonist Therapeutics Inc
Wall Street
Price Targets
PTGX Price Targets Summary
Protagonist Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
PTGX
is 55.4625 USD
with a low forecast of 43.43 USD and a high forecast of 68.25 USD.
PTGX Last Price Targets
Protagonist Therapeutics Inc
The latest public price target was made on Sep 12, 2024 by
Douglas Tsao
from
H.C. Wainwright
,
who expects
PTGX
stock to
rise by 12%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Douglas Tsao
H.C. Wainwright
|
50
USD
Upside 12% |
2 months ago
Sep 12, 2024
|
Protagonist Therapeutics (PTGX) PT Raised to $50 at H.C. Wainwright
StreetInsider
|
|
Douglas Tsao
H.C. Wainwright
|
38
USD
Downside 15% |
5 months ago
Jun 17, 2024
|
H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
StreetInsider
|
Yasmeen Rahimi
Piper Sandler
|
35
USD
Downside 22% |
2 years ago
May 17, 2022
|
Protagonist Therapeutics price target lowered to $35 from $60 at Piper Sandler
TheFly
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PTGX's stock price target?
Price Target
55.4625
USD
According to Wall Street analysts, the average 1-year price target for
PTGX
is 55.4625 USD
with a low forecast of 43.43 USD and a high forecast of 68.25 USD.
What is Protagonist Therapeutics Inc's Revenue forecast?
Projected CAGR
49%
The
compound annual growth rate
of Protagonist Therapeutics Inc's revenue for the next 3 years is
49%.
You don't have any saved screeners yet
